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Animal studies suggest the involvement of natriuretic peptides (NP) in several brain
functions that are known to be disturbed during Alzheimer’s disease (AD). However,
it remains unclear whether such findings extend to humans. In this study, we aimed to:
(1) map the gene expression and localization of NP and their receptors (NPR) in human
post-mortem brain tissue; (2) compare the relative amounts of NP and NPR between
the brain tissue of AD patients and non-demented controls, and (3) compare the relative
amounts of NP between the cerebrospinal fluid (CSF) of AD patients and non-demented
controls. Using the publicly available Allen Human Brain Atlas dataset, we mapped the
gene expression of NP and NPR in healthy humans. Using immunohistochemistry, we
visualized the localization of NP and NPR in the frontal cortex of AD patients (n = 10,
mean age 85.8± 6.2 years) and non-demented controls (mean age = 80.2± 9.1 years).
Using Western blotting and ELISA, we quantified the relative amounts of NP and NPR in
the brain tissue and CSF of these AD patients and non-demented controls. Our results
showed that NP and NPR genes were ubiquitously expressed throughout the brain in
healthy humans. NP and NPR were present in various cellular structures including in
neurons, astrocyte-like structures, and cerebral vessels in both AD patients and non-
demented controls. Furthermore, we found higher amounts of NPR type-A in the brain
of AD patients (p = 0.045) and lower amounts of NP type-B in the CSF of AD patients
(p = 0.029). In conclusion, this study shows the abundance of NP and NPR in the brain
of humans suggesting involvement of NP in various brain functions. In addition, our
findings suggest alterations of NP levels in the brain of AD patients. The role of NP in the
development and progression of AD remains to be elucidated.
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INTRODUCTION
Natriuretic peptides (NP) refer to a group of peptides that
are mostly known for their actions within the cardiovascular
system (Potter et al., 2006). NP are mainly secreted from
cardiac myocytes in response to cardiac wall stretch and volume
expansion. Consequently, NP regulate body fluid homeostasis by
inducing natriuresis, diuresis, vasodilation and lowering blood
pressure (Potter et al., 2006). Three members of this family are
atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP),
and C-type natriuretic peptide (CNP) (Suzuki et al., 2001).
The biological activities of NP are mediated through activation
of three transmembrane receptors including natriuretic peptide
receptor A (NPR-A), natriuretic peptide receptor B (NPR-B),
and natriuretic peptide receptor C (NPR-C) (Potter et al., 2006;
Figure 1). While NP were initially discovered in cardiac myocytes
(de Bold et al., 1981), extensive distribution of NP and their
receptors in the brain of animal species has been repeatedly
reported (Cao and Yang, 2008). NP and their receptors were
shown to be present in various neuronal structures, glial cells
and cerebral vessels (Cao and Yang, 2008; Prado et al., 2010).
Notably, findings from animal studies suggest that NP may
regulate neuroplasticity (Decker et al., 2010), blood-brain barrier
integrity (Bohara et al., 2014), neuro-inflammation (Moriyama
et al., 2006; James et al., 2010) and memory function (Telegdy
et al., 2000; Decker et al., 2009).
The biological roles of NP in the central nervous system
(CNS) have been mainly described in rodent and mammalian
species (Mahinrad et al., 2016). Existing evidence from humans
indicates that higher plasma levels of NP associate with dementia
and accelerated cognitive decline (van der Velpen et al., 2017).
Although this link was mainly attributed to cardiovascular
pathologies (Wang et al., 2004), recent findings suggest that
plasma NP associate with cognitive decline independent of
cardiovascular disease (Wijsman et al., 2014; Sabayan et al.,
2015). Moreover, higher plasma levels of BNP were linked with
lower cerebrospinal fluid (CSF) amyloid beta42 (Aβ42) and total
tau/Aβ42 ratios (Hu et al., 2012). Interestingly, some studies have
reported the presence of NP and their receptors in brain tissue
and CSF of humans (Ogawa et al., 1992; Kaneko et al., 1993).
Hence, we have recently hypothesized that NP may be potential
diagnostic and/or therapeutic markers for Alzheimer’s disease
(AD) (Mahinrad et al., 2016).
To substantiate this hypothesis, in this study we aimed
to: (1) map the gene expression and localization of NP and
their receptors (NPR) in human post-mortem brain tissue; (2)
compare the relative amounts of NP and NPR between the
brain tissue of AD patients and non-demented controls, and (3)




We had access to biomaterials of 17 non-demented controls
(mean age = 80 ± 8.5 years, 59% female) and 10 patients with
a definitive pathological diagnosis of AD (mean age 85.8 ± 6.2
years, 60% female) (Table 1). The definitive diagnosis of the
donors was provided by expert neuropathologists that considered
both histopathological results and the clinical diagnosis of the
donors. To investigate the localization of NP and NPR in the
brain, we performed immunohistochemistry using post-mortem
brain tissue of a subset of 13 non-demented controls and 10 AD
patients (Table 1). For quantitative assessment of NP and NPR
in the brain, we performed Western blotting using a subset of
donors from whom frozen brain tissue was available (10 controls
and 8 AD patients, Table 1). NP in the CSF were detected
by enzyme-linked immunosorbent assay (ELISA) in another
subset of the donors that had a frozen CSF sample available (10
controls and 10 AD patients, Table 1). Age and gender were not
significantly different between controls and AD patients in any of
the subsets (all p > 0.05).
Brain Tissue and CSF Samples
Post-mortem brain tissue from the frontal lobe – middle
frontal gyrus – of 10 AD patients and 8 controls were obtained
from the Netherlands Brain Bank (NBB, Netherlands Institute
for Neuroscience Amsterdam); and for 6 controls tissues
were obtained from the Normal Aging Brain Collection
Amsterdam (NABCA). All CSF samples were provided by
the NBB. The CSF was collected from the lateral ventricles
during autopsy and stored at −80◦C for later analysis. All
donors gave written informed consent for brain autopsy
and for the use of their specimens and medical records for
research purposes. According to national ethical guidelines,
all samples were coded to maintain the anonymity of
donors.
Gene Expression Data
To investigate the gene expression of NP and NPR in the brain,
we used BrainScope (Huisman et al., 2017).1 BrainScope is a
web-portal for visual analysis of gene expression in the brain of
healthy humans, based on data from the Allen Human Brain
Atlas (Hawrylycz et al., 2012; Hawrylycz et al., 2015).2 The Allen
Human Brain Atlas provides the mRNA expression of about
20,000 genes using six healthy adult donors (age range 24 to
57 years). Gene expression was measured with a customized
micro-array chip using ∼3,700 samples taken from anatomically
annotated regions of the brain. From this data, BrainScope uses
105 expression values per gene corresponding to anatomically
annotated brain regions that were sampled for all the six
donors. The expression values were averaged to provide a single
expression value for each sample across the individuals (Huisman
et al., 2017). Accordingly, we used BrainScope to explore the
expression of the following genes: natriuretic peptide A (NPPA,
encodes ANP protein, Gene ID 4878), natriuretic peptide B
(NPPB, encodes BNP protein, Gene ID 4879), natriuretic peptide
C (NPPC, encodes CNP protein, Gene ID 4880), natriuretic
peptide receptor 1 (NPR1, encodes NPR-A protein, Gene ID
4881), natriuretic peptide receptor 2 (NPR2, encodes NPR-B
1http://brainscope.nl/brainscope
2http://human.brain-map.org/static/download
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FIGURE 1 | Schematic presentation of the ligand preference of natriuretic peptide receptors. Natriuretic peptides bind to three transmembrane receptors, namely
NPR-A, NPR-B, and NPR-C. ANP and BNP bind to NPR-A; CNP binds to NPR-B and all the NP (ANP, BNP, and CNP) bind to NPR-C. Activation of the NPR
increases the intracellular concentration of cyclic guanosine monophosphate which is the main mediator of the biological activities of NP. NPR-C is a clearance
receptor. ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; NPR-A, natriuretic peptide receptor A; NPR-C, natriuretic peptide receptor C; GTP, guanosine
triphosphate; cGMP, cyclic guanosine monophosphate.
protein, Gene ID 4882) and natriuretic peptide receptor 3 (NPR3,
encodes NPR-C protein, Gene ID 4883).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were serially cut
into 5-µm-thick sections and mounted on coated glass slides
(SuperFrost R©Plus, VWR). The sections were deparaffinized in
xylene and rehydrated through graded ethanol concentrations
(100, 90, and 70%). To block endogenous peroxidase activity,
the sections were incubated for 20 min in methanol with
0.3% hydrogen peroxide (H2O2). This was followed by antigen
retrieval by cooking the sections for 20 min at 0.76 bar steam
pressure in an acidic pH 6 solution (H-3300, Vector labs).
The antigen retrieval step was performed depending on the
primary antibody (Supplementary Table 1). Next, the sections
were washed in phosphate-buffered saline (PBS) and incubated
with the primary antibody overnight at room temperature
in the blocking buffer (1% bovine serum albumin [BSA]
in PBS). The sections were then incubated for 1 h with a
biotin-labeled secondary anti-rabbit or anti-mouse antibody
followed by 30 min incubation with avidin-biotin complex (ABC,
Vector Labs, CA, United States). For the anti-NPR-C primary
antibody, the secondary antibody was conjugated to horseradish
peroxidase(HRP) instead of biotin. Staining was visualized
using 3,3′-Diaminobenzidine (DAB) which was activated by
H2O2. Finally, the sections were counterstained with Harris
Haematoxylin and coverslipped with Entellan. The sections were
scanned using an automatic bright field slide scanner (Philips
IntelliSite Ultra Fast Scanner, Digital pathology slide scanner,
Netherlands) for microscopic evaluation.
All sections were evaluated for the presence/absence of NP
or NPR staining in the gray matter (GM), white matter (WM)
and cerebral vessels. The assessments were performed by two
trained observers (SM and IV) who were blinded to the clinical
diagnosis of the donors. Disagreements (n = 151 cases, 9.8% of the
sections) between the two reviewers were resolved by discussion
with the third reviewer (MB). For semi-quantitative comparisons,
we compared the percentage of the positively scored subjects
(presence of signal) between AD patients and controls for each
protein of interest.
Protein Isolation and Western Blotting
The frozen brain tissues were chopped in GM and WM on
dry ice. We were not able to separate the WM of four AD
patients due to severe atrophy of the brain tissue. Next, the
GM and WM samples were suspended in lysis buffer (50 mM
tris pH 7.5 and 1% triton in 10 ml Milli-Q) supplemented with
cOmplete Mini Protease Inhibitor Cocktail Tablets (Roche). This
was followed by homogenizing the samples in a bullet blender
electric homogenizer (Next Advance) for 3 min using 0.5 mm
stainless steel beads. The homogenized samples were centrifuged
for 30 min at full speed before collection of the supernatants.
Protein concentration was calculated using the bicinchoninic acid
kit (Thermo Fisher Scientific, Waltham, MA, United States) with
bovine serum albumin as a standard. The supernatant was further
diluted in sample buffer and denatured by boiling for 10 min
in 95◦.
We used 50 µg of the GM and WM protein lysates per sample.
Proteins were separated by SDS-PAGE by running through a
sodium dodecyl sulfate 4–20% polyacrylamide gradient gel (Bio-
Rad) alongside a proteins size marker (PageRulerTM, Thermo
Fisher Scientific). Proteins were transferred to a nitrocellulose
membrane using the Trans-blot Turbo Transfer system (Bio-
Rad) for 30 min at 1.0 A. The transfer of proteins was checked
with Ponceau red followed by washing the membrane in Tris-
Buffered Saline (TBS). The membrane was blocked in 5% low
fat milk in TBS-Tween (mTBST) for 1 h and incubated with
primary antibody (diluted in 5% mTBST) at room temperature
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TABLE 1 | Characteristics of study participants.
Diagnosis Source Age Gender PMD (h) IHC WB CSF CSF pH
Control NBB 84 F 5 : 36 6.68
Control NBB 70 F 7 : 35 NA 6.03
Control NBB 64 F 5 : 40 NA NA
Control NBB 83 M 5 : 15 NA 6.60
Control NBB 91 F 3 : 47 6.27
Control NBB 73 M 8 : 00 5.37
Control NBB 72 F 6 : 50 7.22
Control NBB 89 F 6 : 30 6.55
Control NBB 88 M 11 : 10 NA NA 5.98
Control NBB 82 M 5 : 20 NA NA 5.85
Control NBB 73 F 5 : 30 NA NA 6.38
Control NABCA 82 M 5 : 30 NA NA
Control NABCA 87 F 8 : 30 NA
Control NABCA 72 F 7 : 15 NA
Control NABCA 93 M 8 : 30 NA
Control NABCA 82 M 7 : 30 NA
Control NABCA 73 F 6 : 30 NA NA
AD NBB 88 M 5 : 30 6.72
AD NBB 85 F 4 : 05 6.47
AD NBB 86 M 5 : 10 NA 6.61
AD NBB 81 M 7 : 50 6.15
AD NBB 88 F 4 : 40 6.39
AD NBB 73 M 4 : 45 6.48
AD NBB 96 F 7 : 55 5.90
AD NBB 82 F 4 : 35 NA 6.53
AD NBB 90 F 3 : 55 6.24
AD NBB 89 F 4 : 30 6.73
AD, Alzheimer’s disease; NBB, Netherlands Brain Bank; NABCA, Netherlands Aging Brain Collection Amsterdam; PMD, post-mortem delay (in hours); IHC,
immunohistochemistry; WB, Western blot; NA, not available; CSF, cerebrospinal fluid.
for 90 min, 2 h or overnight at −4◦, depending on the
antibody used. After washing in TBS buffer, the membrane
was incubated with secondary antibodies: anti-rabbit or anti-
mouse IRDye800CW (LI-COR, Lincoln, NE, United States) at
1:5000 for 1.5 h. For β-actin loading control, the membrane was
incubated with mouse β-actin at 1:5000 followed by a secondary
anti Mouse IRDye680CW antibody (LI-COR, Lincoln, NE,
United States). Target bands were visualized using an Odyssey
infrared imaging system (LI-COR). The relative densities of the
bands were measured using Image Studio Lite software (version
5.0).
CSF Analysis Using ELISA
The frozen CSF samples were shipped to Johns Hopkins
University, Baltimore, MD, United States, for ELISA
experiments. ANP, BNP, and CNP were measured using
commercial ELISAs following the manufacturer’s protocol
(ALPCO, Salem, NH, United States), except that CSF was
concentrated prior to analysis by centrifugation/lyophilisation.
For ANP and BNP, samples were reconstituted or diluted in
diluent 35 (Mesoscale Diagnostics, Rockville, MD, United States)
and for a subset of donors CSF was spiked with a mid-range NP
standard and recovery was assessed. A sandwich pro-ANP ELISA
(1–98) was used to quantify ANP where CSF samples taken
to dryness were resuspended in a volume to generate a 5-fold
concentration. The sensitivity of the assay was 0.05 nmol/L and
the dynamic range was 0.63 to 10 nmol/L. The amino terminal
BNP fragment (nt-pro-BNP 8–29) was measured by competitive
ELISA where CSF samples were also concentrated 5-fold.
Under the conditions used in the laboratory, the sensitivity
was 34 pmol/L and the dynamic range was between 40 and
1600 pmol/L. Determination of levels of amino-terminal pro-
CNP was performed using a sandwich ELISA where CSF was
diluted 1:30 with diluent 35 prior to analysis. The sensitivity
was 0.7 pmol/L and the dynamic range was 0.1 to 128 pmol/L.
When 9 CSF samples were spiked with 1.25 nmol/L pro-ANP,
the recovery was 87± 9%. Nine samples spiked with 400 pmol/L
pro-BNP yielded a recovery of 103 ± 5%, while for 9 samples
spiked with 20 pmol/L pro-CNP the recovery was 93± 5%.
Statistical Analysis
The semi-quantitative immunohistochemistry scores were
compared between AD patients and controls using x2 test.
Depending on the distribution of the western blot or CSF
measures-, unpaired two-tailed t-test or Mann–Whitney U-test
were used to compare between AD patients and controls.
We used Pearson correlation coefficient to assess the effect of
postmortem delay on NP or NPR levels in postmortem brain
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tissue and ventricular CSF. Statistical analyses were performed
using SPSS software and a p-value < 0.05 was considered as
statistically significant.
RESULTS
Gene Expression of NP and NPR in the
Brain of Healthy Humans
Figure 2 shows the mean expression of genes coding for NP
and NPR across the brains of six healthy human donors from
the Allen Human Brain Atlas. The NP and NPR genes were
expressed throughout the CNS, although the different NP had
distinctly diverse regional expression levels. In particular, the
gene coding for ANP (NPPA) had the highest expression in
cortical regions and hippocampus, followed by a lower expression
in the telencephalic white matter regions (TEWM) and the lowest
expression in the subcortical structures. In contrast, the gene
coding for BNP (NPPB) had the highest expression in subcortical
structures (hippocampus and basal ganglia), followed by a lower
expression in the TEWM and very low expression throughout
the cortical regions. The gene coding for CNP (NPPC) had the
highest expression in subcortical structures (thalamic nuclei and
hippocampus), followed by a lower expression in the cortical
regions and the lowest expression in TEWM. The gene coding
for NPR-A (NPR1) had the highest expression in subcortical
structures (basal ganglia and hippocampus), followed by a lower
expression in cortical regions and the lowest expression in the
TEWM. The genes coding for NPR-B (NPR2) and NPR-C (NPR3)
had the highest expression in subcortical structures (basal ganglia
FIGURE 2 | Expression of natriuretic peptides’ and natriuretic peptide receptors’ genes in the healthy human brain. The mRNA expression of genes coding for
natriuretic peptides and natriuretic peptide receptors is shown in a coronal view of the left hemisphere. The Expression of each gene is z-score normalized to the
average expression of the gene in the whole brain. Data from the Allen Human Brain Atlas (http://human.brain-map.org/) is visualized using the BrainScope portal
(http://www.brainscope.nl/). CgG: cingulate gyrus; PrG: precentral gyrus; PoG: postcentral gyrus; SMG: supramarginal gyrus; LIG: long insular gyrus; STG: superior
temporal gyrus; ITG: inferior temporal gyrus; HIF: hippocampal formation; BG: basal ganglia and TEWM: telencephalic white matter.
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and hippocampus) followed by a very low expression in cortical
and TEWM regions.
Localization of NP and NPR in the Brain
Tissue of AD Patients and Controls
In the cortex of controls, the immunohistochemistry study
showed positive staining of all NP and NPR proteins in the
neuronal structures. ANP, BNP, and CNP positive stainings were
observed in the cytoplasmic body and neuronal processes of
pyramidal neurons (layers II–VI) (Figures 3A–C, respectively).
BNP-positive staining was mainly localized to Nissl bodies that
were characterized as granular bodies within the cytoplasm of
neurons (Figure 3B). In addition, the CNP-positive staining
was observed in networks of short and long fibers throughout
the cortex (Figure 4A). NPR-A, NPR-B, and NPR-C positive
stainings were also localized to the cytoplasmic body and
neuronal processes of pyramidal neurons (II–VI) (Figures 5A–C,
respectively). Furthermore, a strong NPR-A positive staining was
observed in the Nissl body of neurons throughout the cortex.
These Nissl bodies were characterized as large granular bodies in
the cytoplasm with a stronger staining pattern compared to the
cytosol of neurons (Figure 4B). In addition to the cytoplasm, the
NPR-B-positive neurons also showed a prominent staining in the
nucleolus of neurons (Figure 4C). We observed no staining in
the negative control sections using only the secondary antibody
(Supplementary Figure 1).
In the WM, we observed ANP-positive astrocytes-like
structures that consisted of short packed processes (Figure 3D).
These astrocytes-like structures were spread throughout the
WM, occasionally associated with blood vessels and their cell
bodies were not always distinct. Some ANP-positive astrocytes-
like structures were also observed throughout the cortical layers.
Similarly, we observed NPR-positive astrocyte-like staining in
the WM of some controls (Figures 5D–F). We did not observe
BNP or CNP-positive astrocyte-like structures in the WM or GM
(Figures 3E,F). Other glial cells were not stained for NP or NPR.
In the cerebral vessels, ANP-positive staining was observed in
the leptomeningeal and parenchymal vessels, and was localized
to the endothelium and smooth muscle layers (Figure 3G). BNP-
positive staining was only weakly present in the endothelium of
some leptomeningeal vessels (Figure 3H), while CNP staining
was not detected in the cerebral vessels at all (Figure 3I). NPR-
A and NPR-B stainings were positive in the endothelium and
smooth muscle layers of leptomeningeal and parenchymal vessels
(Figures 5G,H), while NPR-C staining was less prominent in the
cerebral vessels (Figure 5I). Supplementary Figures 2, 3 show
the localization of the NP and NPR in the frontal lobe of AD
patients. We observed a similar pattern of NP and NPR staining
in the frontal lobe of AD patients and controls. Finally, our
semi-quantitative results showed a higher percentage of NPR-
A-positive astrocytes-like structures in AD patients compared to
controls (70% positive staining in AD patients vs 23% positive
staining in controls, x2 = 5.07, df = 1, p = 0.024). The staining
FIGURE 3 | Localization of ANP, BNP, and CNP in the frontal cortex of non-demented controls. NP immunohistochemistry in the frontal lobe (middle frontal gyrus) of
non-demented controls. (A–C) ANP, BNP, and CNP-positive neurons. Arrows point to the cytoplasm (ANP and CNP), neuronal processes (ANP and CNP), and Nissl
bodies (BNP); (D) ANP-positive astrocyte-like cells in the white matter; (E,F) negative BNP and CNP staining in the white matter; (G) ANP-positive endothelium and
smooth muscles; (H) BNP-positive endothelium, and (I) negative CNP staining in the leptomeningeal vessels.
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FIGURE 4 | Immunohistochemistry of CNP, NPR-B, and NPR-A in the gray matter of non-demented controls. (A) Immunohistochemistry of CNP in the gray matter.
Arrows point to CNP-positive fibers in the gray matter; (B) Immunohistochemistry of NPR-A in the gray matter. Arrow point to the granular bodies resembling Nissl
bodies in the cytoplasm of neuron, and (C) Immunohistochemistry of NPR-B in the gray matter. Arrow point to the nucleolus of the neuron.
FIGURE 5 | Localization of NPR-A, NPR-B, and NPR-C in the frontal cortex of non-demented controls. NPR immunohistochemistry in the frontal lobe (middle frontal
gyrus) of non-demented controls. (A–C) NPR-A, NPR-B, and NPR-C-positive neurons. Arrows point to the cytoplasm (all NPR), neuronal processes (all NPR), and
Nissl bodies (NPR-A); (D–F) NPR-A, NPR-B, and NPR-C-positive astrocyte-like cells in the white matter; (G–I) NPR-A, NPR-B, and NPR-C-positive endothelium and
smooth muscles in leptomeningeal vessels.
in other structures including neurons and leptomeningeal vessels
were not significantly different between AD patients and controls
(Supplementary Table 2).
Quantitative Comparison of NP and NPR
in Brain Tissue Between AD Patients and
Controls
For quantitative comparisons in brain tissue, we performed
Western blots using GM and WM samples isolated from each
donor. Using an antibody that binds to ANP, we observed an
expected band of ∼17 kDa in both AD patients and controls
(Supplementary Figure 4). ANP was abundant in the GM, but
virtually absent in the WM. Using an antibody against NPR-A,
we observed specific bands of ∼150 kDa in both AD patients
and controls. The NPR-A specific bands were highly pronounced
in the GM while no or very weak bands were present in the
WM (Supplementary Figure 4). Bands reacting with anti-NPR-
C antibody were observed at ∼60 kDa in both AD patients
and controls; and in GM and WM samples (Supplementary
Figure 4). We were not able to detect any BNP, CNP, or NPR-B
specific signals despite the use of different antibodies. Figure 6
shows quantification of Western blot bands in the GM of AD
patients and controls. We found significantly higher amounts
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FIGURE 6 | Relative amounts of ANP, NPR-A, and NPR-C in the gray matter of non-demented controls and Alzheimer’s disease patients. (A) NPR-A and β-Actin
Western blot bands in AD patients and non-demented controls; (B) quantification of NPR-A Western blots between AD patients and controls; (C) NPR-C and
β-Actin Western blot bands in AD patients and non-demented controls; (D) quantification of NPR-C Western blots between AD patients and controls; (E) ANP and
β-Actin Western blot bands in AD patients and non-demented controls, and (F) quantification of ANP Western blots between AD patients and controls. Bars show
the mean (standard deviation) of the normalized signals. Analyses were performed using t-test for NPR-A and Mann-Whitney U-test for NPR-C and ANP. ∗p < 0.05.
ANP, atrial natriuretic peptide; NPR-A, natriuretic peptide receptor A; NPR-C, natriuretic peptide receptor C; AD, Alzheimer’s disease.
of NPR-A in the GM of AD patients compared to controls
[t(16) = -2.18, p = 0.045, independent sample t-test]. NPR-C
signals appeared to be higher in the GM of controls, although
the differences between AD patients and controls were not
statistically different (Mann–Whitney U = 18.0, p = 0.051 two-
tailed). Similarly, ANP signals were not significantly different
between AD patients and controls (Mann–Whitney U = 33.0,
p = 0.534). In the WM, none of the Western blot bands was
significantly different between AD patients and controls (data not
shown). Finally, there was no significant relationship between the
postmortem delay and ANP, NPR-A or NPR-C levels in the brain
tissue (ANP r = -0.45, NPR-A r = -0.21, and NPR-C r = 0.38; all
p-values > 0.05).
When comparing between GM and WM, ANP, and NPR-
A-specific signals were significantly higher in GM compared to
WM (p < 0.001), while NPR-C-specific signals were not different
between GM and WM. Comparison of the gene expression
data (Figure 2) with our Western blot findings (Figure 6)
showed similar patterns: the genes coding for ANP and NPR-
A were highly expressed in the cortex (expression z-score > 0)
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compared to the TEWM (expression z-score < -1). On the other
hand, the gene coding for NPR-C had low mRNA expression
in both GM and WM (expression z-score < 0 in GM and
WM).
Quantitative Comparison of NP in the
CSF Between AD Patients and Controls
Atrial natriuretic peptide (ANP), BNP, and CNP levels in the
CSF ranged from 56.48 to 192.36 pmol/L, 44.12 to 127.39 pmol/L
and 125.25 to 1180.13 pmol/L, respectively. We did not find any
significant relationship between postmortem delay and NP levels
in the CSF (ANP r = -0.04, BNP r = 0.22 and CNP r = 0.17; all
p-values > 0.05). Furthermore, there was no relationship between
CSF pH and NP levels in the CSF (ANP r = -0.05, BNP r = -
0.07 and CNP r = -0.17; all p-values > 0.05). Figure 7 shows the
comparison of ANP, BNP and CNP levels between AD patients
and controls in post-mortem CSF. We observed significantly
lower amounts of BNP in the CSF of AD patients compared
to controls (Mann–Whitney U = 21.0, p = 0.029 two-tailed).
Similarly, ANP and CNP levels appeared to be lower in the CSF
of AD patients although these differences were not statistically
significant (Figure 7).
DISCUSSION
In this study, we first showed that the genes coding for
NP and NPR are ubiquitously expressed across the brain
of healthy humans. We detected NP and NPR proteins in
neuronal structures, cerebral vessels, and in structures resembling
astrocytes in the frontal lobe of non-demented individuals and
patients with AD. When comparing between AD patients and
non-demented controls, NPR-A levels were higher in the brain
tissue of AD patients while BNP levels were lower in the CSF of
AD patients.
Previous animal studies have detected the expression and
localization of NP and NPR in numerous structures of the
CNS (Mahinrad et al., 2016). For example, ANP was detected
in neuronal structures of the hypothalamus, telencephalon, and
cerebellum (Cao and Yang, 2008), and in the astrocytes of human
and canine cortex (McKenzie, 1992; McKenzie et al., 1994).
Similarly, BNP and CNP were found to be widely distributed
in the neuronal structures of the cerebral cortex, hypothalamus,
spinal cord, and retina (Cao and Yang, 2008; Mahinrad et al.,
2016). Furthermore, the receptors for ANP and BNP were
detected on the luminal membrane of cerebral vessels in vitro
and in vivo (Ermisch et al., 1991; Gelfand et al., 1991). Despite
the wealth of evidence from animal studies, limited data on the
distribution and expression of NP in the brain of humans is
available. In this study, we extended the evidence from animal
species to human by providing a detailed mapping of NP and
NPR in the frontal lobe of humans. As in animal species, in
humans the expression of NP and NPR genes seems to be
complementary in various brain regions (Cao and Yang, 2008).
This suggests that NP are not only produced in cardiac myocytes,
but are also locally produced in the CNS of humans (Cao and
Yang, 2008). Furthermore, we found that NP and NPR are present
in various cellular structures of the frontal lobe, suggesting a
wide range of NP functions in the human brain. In particular,
the presence of NP and NPR in both neuronal and cerebral
vessels might indicate a potential role of NP in neurovascular
functioning (Iadecola, 2004). In line with this, recent in vitro
studies have shown that administration of ANP and BNP resulted
in a significant dose-dependent relaxation of the middle cerebral
artery and basilar artery (Guo et al., 2015). On the other hand, NP
might also be involved in synaptic transmission and processing
of information. In support of this, animal and in vivo studies
have demonstrated that NP regulate the release and re-uptake of
neurotransmitters such as noradrenalin, dopamine and glycine
(Mahinrad et al., 2016). We could also detect ANP and NPR
in structures resembling astrocytes in the WM. Specifically,
we found that NPR-A positive astrocytes-like cells were more
frequently observed in AD patients compared to controls. This
is consistent with previous studies showing the presence of ANP
and NPR in astrocyte of the cortex (McKenzie, 1992), suggesting
a potential role of astrocytes in physiological functions of NP
in the brain (Mahinrad et al., 2016). Further experiments using
specific antibodies against astroglia cells will verify the identity
of these astrocyte-like structure. Collectively, our qualitative
and gene expression data are consistent with previous animal
studies indicating NP as neuropeptides that might regulate
several functions in the brain (Hodes and Lichtstein, 2014).
Nevertheless, future research is needed to further disentangle
the putative role(s) of centrally acting NP in the brain of
humans.
Given the involvement of NP in several of the pathological
pathways that are also disturbed during AD, we have recently
hypothesized NP as potential markers for diagnosis and/or
treatment of AD (Mahinrad et al., 2016). We postulated
that decreased action of NP in the brain might impair the
structural and/or functional integrity of the brain and predispose
individuals to a higher risk of cognitive decline (Mahinrad et al.,
2016). In line with this hypothesis, we found lower levels of
BNP in the CSF of AD patients, coupled with higher amounts
of NPR-A in the brain tissue of AD patients. This may suggest
impaired function of NP in the brain of AD patients, which
could in turn accelerate neuro-inflammation, oxidative stress and
neurodegeneration. Such alteration may ultimately hamper the
functional and/or structural integrity of the brain and predispose
individuals to a higher risk of cognitive decline. One explanation
for reduced levels of BNP in the CSF could be attributed to their
elevated levels in the systemic circulation. In fact, systemic and
central NP might act in a feedback loop such that increased
NP in the plasma inhibits production and/or biological activity
of NP in the brain (Pemberton et al., 2002; Mahinrad et al.,
2016). In line with this, previous research has shown that higher
levels of BNP in the plasma of ovine sheep associates with
decreased BNP levels in the hypothalamus (Pemberton et al.,
2002). Interestingly, recent findings in humans suggest that
higher plasma BNP associates with lower CSF Aβ42 and higher
t-tau/Aβ42 ratios (Hu et al., 2012).Collectively, our pilot results
point toward a potential role of NP in the pathology of AD.
Nevertheless, larger scale studies are needed to replicate our
findings and explore the potential association of centrally acting
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NP with markers of neurodegeneration. In addition, it should
be noted that our results cannot directly be extrapolated to
lumbar CSF since we used ventricular CSF in our experiments.
In this setting, future research should determine the potential
differences in NP levels between ventricular and lumbar CSF.
Furthermore, it is not known whether post-mortem delays
affect the quantification of NP in the brain. In this study, we
did not find a significant correlation between NP levels and
postmortem delay, but more detailed studies are needed to
further assess this potential confounding effect. Finally, the effect
of cardiovascular risk factors, cardiovascular co-morbidities and
use of medications on NP in the brain should be addressed in
future.
We used frontal lobe to detect NP and NPR in the brain
tissue of AD patients and non-demented controls. Although
hippocampus is the primary brain region being affected during
AD, frontal lobe involvement is also a well-described feature
of AD pathology (Laakso et al., 1995; Lehtovirta et al., 1995;
Du et al., 2007). Furthermore, atrophy of the middle frontal
gyrus has been demonstrated in patients with mild cognitive
impairment (Apostolova and Thompson, 2008). It is worth
mentioning that previous research in animals have detected
NP and NPR in various brain regions such as hippocampus,
thalamus and hypothalamus (Cao and Yang, 2008). Consistent
with this, we observed high expression of NP and NPR in the
subcortical structures including hippocampus and hypothalamus
in healthy humans. In this setting, future studies focusing
on other brain regions are needed to further disentangle the
localization and function of NP in different brain regions of
humans.
In summary, we showed the widespread presence of all NP
and their receptors in the brain of humans. In line with our
hypothesis, we observed higher amounts of NPR-A in the brain
tissue and lower levels of BNP in the CSF of AD patients. These
findings further highlight that NP may be potential markers
for AD. Given the widespread distribution of NP in different
structures of the human brain, future research should determine
the specific function of NP in the brain of humans, in health and
disease. Finally, the inherent presence of NP in the brain and their
easy availability in clinical practice are among the key factors that
can accelerate the utility of NP as disease modifying agents in
cognitive impairment and AD.
FIGURE 7 | ANP, BNP, and CNP in the post-mortem cerebrospinal fluid of non-demented controls and Alzheimer’s disease patients. Bars represent the mean
(standard deviation) of each NP in the cerebrospinal fluid of AD patients and controls. Analyses were performed using Mann–Whitney U test. ∗p < 0.05. CSF,
cerebrospinal fluid; AD, Alzheimer’s disease; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C-type natriuretic peptide; SD, standard deviation.
Frontiers in Neuroscience | www.frontiersin.org 10 November 2018 | Volume 12 | Article 864
fnins-12-00864 November 22, 2018 Time: 18:7 # 11
Mahinrad et al. Natriuretic Peptides in Alzheimer’s Disease
AUTHOR CONTRIBUTIONS
SM designed the experiments, performed the immunohisto-
chemistry and western blot experiments, analyzed and
interpreted the data, and drafted and revised the
manuscript. MB designed the experiments, interpreted
the immunohistochemistry and western blot data, and
critically reviewed the manuscript. IvdV analyzed the
immunohistochemistry data, collected the CSF data, and drafted
and revised the manuscript. AM analyzed and interpreted the
gene expression data, and critically reviewed the manuscript.
WvR-M interpreted the immunohistochemistry and western blot
data, and critically reviewed the manuscript. NF performed the
ELISA measurements in CSF, and drafted and critically reviewed
the manuscript. SY performed the ELISA measurements in CSF
and critically reviewed the manuscript. BS, DvH, and LvdW
conceived and designed the study, interpreted the data, and
critically reviewed the manuscript.
FUNDING
This work was supported by a grant from CardioVasculair
Onderzoek Nederland (CVON) Heart-Brain Connection
(HBC) consortium; partially supported by grants from
the European Union 7th Framework Programs BrainPath
(PIAPP-GA-2013–612360) and Switchbox (Health-F2-2010-
259772). IvdV was partially supported by a grant from
Alzheimer Nederland. LvdW and LM van der Graaf were
supported by the Bontius stichting (Leiden, Netherlands)
and by the Netherlands Organization for Scientific Research
(NWO), under research program VIDI, project “Amyloid
and vessels,” number 864.13.014. The measurements in CSF
were supported in part by the National Center for Advancing
Translational Sciences, NIH #UL1TR001079 and #R37AG19905
grants.
ACKNOWLEDGMENTS
We would like to thank the Netherlands Brain Bank (Amsterdam,
Netherlands) and Normal Aging Brain Collection Amsterdam
for supplying brain tissue samples. We thank Mr. Gerrit
Kracht for his valuable contribution in preparation of figures
contained in this article and Ms. Linda M. van der Graaf for
technical assistance during immunohistochemistry and Western-
blot experiments. We acknowledge the support of the Johns
Hopkins University Institute for Clinical and Translational
Research Clinical Research Core Laboratory for the performance
of NP measures in CSF.
SUPPLEMENTARY MATERIAL




Apostolova, L. G., and Thompson, P. M. (2008). Mapping progressive brain
structural changes in early Alzheimer’s disease and mild cognitive impairment.
Neuropsychologia 46, 1597–1612. doi: 10.1016/j.neuropsychologia.2007.10.026
Bohara, M., Kambe, Y., Nagayama, T., Tokimura, H., Arita, K., and Miyata, A.
(2014). C-type natriuretic peptide modulates permeability of the blood-brain
barrier. J. Cereb. Blood Flow Metab. 34, 589–596. doi: 10.1038/jcbfm.2013.234
Cao, L.-H., and Yang, X.-L. (2008). Natriuretic peptides and their receptors in the
central nervous system. Prog. Neurobiol. 84, 234–248. doi: 10.1016/j.pneurobio.
2007.12.003
de Bold, A. J., Borenstein, H. B., Veress, A. T., and Sonnenberg, H. (1981). A rapid
and potent natriuretic response to intravenous injection of atrial myocardial
extract in rats. Life Sci. 28, 89–94. doi: 10.1016/0024-3205(81)90370-2
Decker, J. M., Wojtowicz, A. M., Bartsch, J. C., Liotta, A., Braunewell, K. H.,
Heinemann, U., et al. (2010). C-type natriuretic peptide modulates bidirectional
plasticity in hippocampal area CA1 in vitro. Neuroscience 169, 8–22. doi: 10.
1016/j.neuroscience.2010.04.064
Decker, J. M., Wojtowicz, A. M., Ul Haq, R., Braunewell, K. H., Heinemann, U.,
and Behrens, C. J. (2009). C-type natriuretic peptide decreases hippocampal
network oscillations in adult rats in vitro. Neuroscience 164, 1764–1775. doi:
10.1016/j.neuroscience.2009.09.036
Du, A. T., Schuff, N., Kramer, J. H., Rosen, H. J., Gorno-Tempini, M. L., Rankin, K.,
et al. (2007). Different regional patterns of cortical thinning in Alzheimer’s
disease and frontotemporal dementia. Brain 130(Pt 4), 1159–1166. doi: 10.1093/
brain/awm016
Ermisch, A., Ruhle, H. J., Kretzschmar, R., and Baethmann, A. (1991).
On the blood-brain barrier to peptides: specific binding of atrial
natriuretic peptide in vivo and in vitro. Brain Res. 554, 209–216.
doi: 10.1016/0006-8993(91)90191-W
Gelfand, R. A., Frank, H. J., Levin, E., and Pedram, A. (1991). Brain and atrial
natriuretic peptides bind to common receptors in brain capillary endothelial
cells. Am. J. Physiol. 261(2 Pt 1), E183–E189. doi: 10.1152/ajpendo.1991.261.2.
E183
Guo, S., Goetze, J. P., Jeppesen, J. L., Burnett, J. C., Olesen, J., Jansen-
Olesen, I., et al. (2015). Effect of natriuretic peptides on cerebral artery blood
flow in healthy volunteers. Peptides 74, 33–42. doi: 10.1016/j.peptides.2015.0
9.008
Hawrylycz, M., Miller, J. A., Menon, V., Feng, D., Dolbeare, T., Guillozet-
Bongaarts, A. L., et al. (2015). Canonical genetic signatures of the adult human
brain. Nat. Neurosci. 18, 1832–1844. doi: 10.1038/nn.4171
Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H., Ng, L., Miller,
J. A., et al. (2012). An anatomically comprehensive atlas of the adult human
brain transcriptome. Nature 489, 391–399. doi: 10.1038/nature11405
Hodes, A., and Lichtstein, D. (2014). Natriuretic hormones in brain function. Front.
Endocrinol. 5:201. doi: 10.3389/fendo.2014.00201
Hu, W. T., Holtzman, D. M., Fagan, A. M., Shaw, L. M., Perrin, R.,
Arnold, S. E., et al. (2012). Plasma multianalyte profiling in mild cognitive
impairment and Alzheimer disease. Neurology 79, 897–905. doi: 10.1212/WNL.
0b013e318266fa70
Huisman, S. M. H., van Lew, B., Mahfouz, A., Pezzotti, N., Hollt, T., Michielsen, L.,
et al. (2017). BrainScope: interactive visual exploration of the spatial and
temporal human brain transcriptome. Nucleic Acids Res. 45:e83. doi: 10.1093/
nar/gkx046
Iadecola, C. (2004). Neurovascular regulation in the normal brain and in
Alzheimer’s disease. Nat. Rev. Neurosci. 5, 347–360. doi: 10.1038/nrn1387
James, M. L., Wang, H., Venkatraman, T., Song, P., Lascola, C. D., and Laskowitz,
D. T. (2010). Brain natriuretic peptide improves long-term functional recovery
after acute CNS injury in mice. J. Neurotrauma 27, 217–228. doi: 10.1089/neu.
2009.1022
Frontiers in Neuroscience | www.frontiersin.org 11 November 2018 | Volume 12 | Article 864
fnins-12-00864 November 22, 2018 Time: 18:7 # 12
Mahinrad et al. Natriuretic Peptides in Alzheimer’s Disease
Kaneko, T., Shirakami, G., Nakao, K., Nagata, I., Nakagawa, O., Hama, N., et al.
(1993). C-type natriuretic peptide (CNP) is the major natriuretic peptide
in human cerebrospinal fluid. Brain Res. 612, 104–109. doi: 10.1016/0006-
8993(93)91649-D
Laakso, M. P., Soininen, H., Partanen, K., Helkala, E. L., Hartikainen, P., Vainio, P.,
et al. (1995). Volumes of hippocampus, amygdala and frontal lobes in the
MRI-based diagnosis of early Alzheimer’s disease: correlation with memory
functions. J. Neural Transm. Par Dis. Dement. Sect. 9, 73–86. doi: 10.1007/
BF02252964
Lehtovirta, M., Laakso, M. P., Soininen, H., Helisalmi, S., Mannermaa, A., Helkala,
E. L., et al. (1995). Volumes of hippocampus, amygdala and frontal lobe in
Alzheimer patients with different apolipoprotein E genotypes. Neuroscience 67,
65–72. doi: 10.1016/0306-4522(95)00014-A
Mahinrad, S., de Craen, A. J., Yasar, S., van Heemst, D., and Sabayan, B. (2016).
Natriuretic peptides in the central nervous system: novel targets for cognitive
impairment. Neurosci. Biobehav. Rev. 68, 148–156. doi: 10.1016/j.neubiorev.
2016.05.022
McKenzie, J. C. (1992). Atrial natriuretic peptide-like immunoreactivity in
astrocytes of parenchyma and glia limitans of the canine brain. J. Histochem.
Cytochem. 40, 1211–1222. doi: 10.1177/40.8.1535643
McKenzie, J. C., Berman, N. E., Thomas, C. R., Young, J. K., Compton, L. Y.,
Cothran, L. N., et al. (1994). Atrial natriuretic peptide-like (ANP-LIR) and ANP
prohormone immunoreactive astrocytes and neurons of human cerebral cortex.
Glia 12, 228–243. doi: 10.1002/glia.440120308
Moriyama, N., Taniguchi, M., Miyano, K., Miyoshi, M., and Watanabe, T. (2006).
ANP inhibits LPS-induced stimulation of rat microglial cells by suppressing
NF-kappaB and AP-1 activations. Biochem. Biophys. Res. Commun. 350, 322–
328. doi: 10.1016/j.bbrc.2006.09.034
Ogawa, Y., Nakao, K., Nakagawa, O., Komatsu, Y., Hosoda, K., Suga, S., et al.
(1992). Human C-type natriuretic peptide. Characterization of the gene and
peptide. Hypertension 19(6 Pt 2), 809–813.
Pemberton, C. J., Yandle, T. G., and Espiner, E. A. (2002). Immunoreactive forms
of natriuretic peptides in ovine brain: response to heart failure. Peptides 23,
2235–2244. doi: 10.1016/S0196-9781(02)00263-2
Potter, L. R., Abbey-Hosch, S., and Dickey, D. M. (2006). Natriuretic peptides,
their receptors, and cyclic guanosine monophosphate-dependent signaling
functions. Endocr. Rev. 27, 47–72. doi: 10.1210/er.2005-0014
Prado, J., Baltrons, M. A., Pifarré, P., and García, A. (2010). Glial cells as sources
and targets of natriuretic peptides. Neurochem. Int. 57, 367–374. doi: 10.1016/j.
neuint.2010.03.004
Sabayan, B., van Buchem, M. A., de Craen, A. J., Sigurdsson, S., Zhang, Q., Harris,
T. B., et al. (2015). N-terminal pro-brain natriuretic peptide and abnormal brain
aging: the AGES-Reykjavik study. Neurology 85, 813–820. doi: 10.1212/WNL.
0000000000001885
Suzuki, T., Yamazaki, T., and Yazaki, Y. (2001). The role of the natriuretic peptides
in the cardiovascular system. Cardiovasc. Res. 51, 489–494. doi: 10.1016/S0008-
6363(01)00238-3
Telegdy, G., Adamik, A., and Glover, V. (2000). The action of isatin (2,3-
dioxoindole) an endogenous indole on brain natriuretic and C-type natriuretic
peptide-induced facilitation of memory consolidation in passive-avoidance
learning in rats. Brain Res. Bull. 53, 367–370. doi: 10.1016/S0361-9230(00)
00359-2
van der Velpen, I. F., Feleus, S., Bertens, A. S., and Sabayan, B. (2017).
Hemodynamic and serum cardiac markers and risk of cognitive impairment
and dementia. Alzheimers Dement. 13, 441–453. doi: 10.1016/j.jalz.2016.
09.004
Wang, T. J., Larson, M. G., Levy, D., Benjamin, E. J., Leip, E. P., Omland, T.,
et al. (2004). Plasma natriuretic peptide levels and the risk of cardiovascular
events and death. N. Engl. J. Med. 350, 655–663. doi: 10.1056/NEJMoa
031994
Wijsman, L. W., Sabayan, B., van Vliet, P., Trompet, S., de Ruijter, W., Poortvliet,
R. K., et al. (2014). N-terminal pro-brain natriuretic peptide and cognitive
decline in older adults at high cardiovascular risk. Ann. Neurol. 76, 213–222.
doi: 10.1002/ana.24203
Conflict of Interest Statement: MB was employed by Percuros BV, Leiden,
Netherlands.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
Copyright © 2018 Mahinrad, Bulk, van der Velpen, Mahfouz, van Roon-Mom,
Fedarko, Yasar, Sabayan, van Heemst and van der Weerd. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Neuroscience | www.frontiersin.org 12 November 2018 | Volume 12 | Article 864
